EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cholesterol-responsive NFE2L1-INSIG1 interaction controls VLDL secretion and metabolic dysfunction–associated steatohepatitis pathogenesis in mice

Shijun Deng, Jessica E Freed, Grace Y Lee, Gizel Askin, Zhe Cao, Özgür Cakici, Bo Yuan, Sheng Tony Hui, Karen E Inouye, Isabel Graupera, Gökhan S Hotamışlıgil

Journal of Clinical Investigation · 15.07.2026 · 136 (14)

DOI: 10.1172/jci197094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.07.2026. Verfasst von Shijun Deng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Metabolism and Center for Prevention and Treatment of Cardiovascular Disease, Harvard TH Chan School of Public Health, Boston…. Hauptthemen laut MEDLINE: Membrane Proteins, Lipoproteins, VLDL, Fatty Liver, Cholesterol. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholesterol overload contributes to metabolic dysfunction–associated steatohepatitis (MASH) progression. One major pathway that limits hepatic cholesterol accumulation is export via VLDL secretion. While sterol regulatory element–binding protein (SREBP) activity is suppressed by insulin-induced gene 1 (INSIG1) under high sterol conditions, VLDL secretion nonetheless persists to prevent lipotoxicity and liver injury, presenting an unresolved paradox in cholesterol sensing and lipoprotein export. Here, we identified a cholesterol-responsive interaction between nuclear factor erythroid 2 related factor-1 (NFE2L1) and INSIG1 that preserved cholesterol homeostasis by sustaining VLDL secretion. Liver-specific NFE2L1 deletion elevated INSIG1 abundance, suppressed SREBP1 activation, and impaired VLDL secretion, leading to hepatic cholesterol accumulation and liver injury. Mechanistically, NFE2L1 bound to INSIG1 via its N-terminal homology box 2 (NHB2) domain; free cholesterol strengthened this interaction to promote INSIG1 degradation, thereby enabling SREBP1 activation and VLDL export. In NFE2L1-deficient mice, WT NFE2L1, but not a mutant NFE2L1 form unable to interact with INSIG1 (NHB2-deleted mutant, ΔNHB2), restored SREBP1 activity and VLDL secretion. Lipidomics analysis revealed that NFE2L1 deficiency reduced serum triglyceride composition, which was restored exclusively by WT NFE2L1. In a murine MASH model, NFE2L1 overexpression activated SREBP1/2, lowered hepatic cholesterol, and attenuated liver injury, inflammation, and fibrosis, without elevating atherogenic lipoproteins owing to compensatory LDL receptor upregulation. Together, these findings explain how VLDL secretion capacity was maintained under cholesterol excess and identify the NFE2L1/INSIG1 axis as a sterol-responsive safeguard for hepatic lipid homeostasis and a potential therapeutic target for MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsLipoproteins, VLDLFatty LiverCholesterolIntracellular Signaling Peptides and ProteinsAnimalsMiceSterol Regulatory Element Binding Protein 1LiverMice, KnockoutHumansMale

Stichwörter der Autor:innen

CholesterolHepatologyInflammationLipidomicsLipoproteinsMetabolism

Substanzen

Membrane ProteinsInsig1 protein, mouseLipoproteins, VLDLSterol Regulatory Element Binding Protein 1Srebf1 protein, mouseCholesterolIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Molecular Metabolism and Center for Prevention and Treatment of Cardiovascular Disease, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
  • Liver Unit Hospital Clínic, Faculty of Medicine and Health Services, University of Barcelona, Barcelona, Spain.
  • Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CiberEHD), Barcelona, Spain.
  • Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Deng, S., Freed, J. E., Lee, G. Y., Askin, G., Cao, Z., Cakici, Ö., Yuan, B., Hui, S. T., Inouye, K. E., Graupera, I., & Hotamışlıgil, G. S. (2026). Cholesterol-responsive NFE2L1-INSIG1 interaction controls VLDL secretion and metabolic dysfunction–associated steatohepatitis pathogenesis in mice. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci197094

Vancouver

Deng S, Freed JE, Lee GY, Askin G, Cao Z, Cakici Ö, et al. Cholesterol-responsive NFE2L1-INSIG1 interaction controls VLDL secretion and metabolic dysfunction–associated steatohepatitis pathogenesis in mice. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci197094

BibTeX
@article{Deng2026,
  author = {Deng, Shijun and Freed, Jessica E and Lee, Grace Y and Askin, Gizel and Cao, Zhe and Cakici, Özgür and Yuan, Bo and Hui, Sheng Tony and Inouye, Karen E and Graupera, Isabel and Hotamışlıgil, Gökhan S},
  title = {Cholesterol-responsive NFE2L1-INSIG1 interaction controls VLDL secretion and metabolic dysfunction–associated steatohepatitis pathogenesis in mice},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {14},
  doi = {10.1172/jci197094}
}
Kostenlos starten →